Novo Nordisk A/s

This study tested whether adding semaglutide (a GLP-1 drug) to a new weekly insulin called insulin icodec helps lower blood sugar in people with type 2 diabetes. 148 adults whose blood sugar was not well controlled on daily insulin alone took part. First, everyone received weekly…

This study looked at how well the diabetes pill Rybelsus® (oral semaglutide) controls blood sugar and weight in adults with type 2 diabetes in Spain. About 465 people took the medicine as prescribed by their doctor and filled out questionnaires about their treatment. The goal was…

This study tested a drug called Ziltivekimab in 264 people with advanced chronic kidney disease and high inflammation. The goal was to find the best dose to lower inflammation and reduce heart risks. Participants received monthly injections of either 7.5 mg, 15 mg, or 30 mg of th…

This study tested a new medicine, NNC0519-0130, in people for the first time. It aims to lower blood sugar and reduce appetite, which could help manage type 2 diabetes and obesity. The trial involved 161 healthy volunteers, overweight individuals, and people with type 2 diabetes,…

This study examined how well oral semaglutide works for controlling blood sugar and body weight in Thai adults with type 2 diabetes. Researchers reviewed medical records of 209 patients over 6 to 12 months. The goal was to see real-world effectiveness in a routine clinic setting.

This study tested whether the diabetes drug semaglutide, taken as a pill, can slow down memory and thinking problems in people with early Alzheimer's disease. About 1,840 adults aged 55-85 with mild cognitive impairment or mild dementia took either the drug or a placebo for up to…

This study tested a new medicine called nonacog beta pegol (N9-GP) in 54 children under 6 with severe haemophilia B, a condition where blood doesn't clot properly. The goal was to see if the drug is safe and effective at preventing and treating bleeding episodes. Children receive…

This study tested a new investigational medicine called CagriSema (a combination of cagrilintide and semaglutide) in 189 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received weekly injections of either CagriSema o…

This study followed 244 adults with type 2 diabetes in Japan who were prescribed Xultophy® by their doctors. Researchers tracked blood sugar levels and any low blood sugar episodes over 26 weeks. The goal was to see how well the drug works in everyday medical practice.

This study tested a new oral medicine called NDec in 96 adults with sickle cell disease. The goal was to see if it safely raises hemoglobin levels and reduces painful crises. Participants took capsules twice a week for about a year, and some also took hydroxyurea. Results will sh…

This study looked at the long-term safety and effectiveness of Ozempic in over 3,200 Japanese adults with type 2 diabetes. Participants took the drug as prescribed by their doctor for about 3 years. Researchers tracked side effects, blood sugar control, and weight changes. The go…

This study tested a new medicine called somapacitan, given as a shot once a week, against the standard daily shot Norditropin in 200 children with growth hormone deficiency. The goal was to see if the weekly shot works as well for helping kids grow and is safe. Children received …

This study followed 155 adults with type 2 diabetes who were prescribed oral semaglutide (Rybelsus) by their doctor. The goal was to see how well the medication lowers blood sugar levels over 8-10 months. Participants completed a questionnaire about how they took their tablets du…

This study followed 291 adults with type 2 diabetes whose blood sugar was not well controlled on their current medication (DPP4i). Participants switched to an oral form of semaglutide, a drug that helps lower blood sugar and may support weight loss. Over about 5–6 months, researc…

This study tested whether semaglutide, a type 2 diabetes medicine taken as a daily pill, can reduce the risk of major heart problems like heart attacks, strokes, or heart-related death. Over 9,600 adults with type 2 diabetes and existing heart disease or risk factors took either …

This study tracked 336 adults with type 2 diabetes in the UK who were already prescribed oral semaglutide (Rybelsus). The goal was to see how well the pill lowers blood sugar and affects body weight in everyday use. Participants took the medication as directed by their doctor and…

This study tested a new insulin that is injected just once a week against a standard daily insulin in 582 adults with type 2 diabetes. The goal was to see if the weekly insulin controls blood sugar as well as the daily one. Participants also used mealtime insulin. The trial laste…

This study looked at whether using a smart insulin pen (NovoPen 6) with two insulins (Tresiba and Fiasp) helps people with type 1 diabetes achieve better blood sugar levels. Over 400 adults used the pen for about 9-11 months, tracking their doses and glucose data via a mobile app…

This study tested a new pen injector for giving the hemophilia A medicine Mim8. The goal was to see if the pen delivers the same amount of medicine into the blood as a standard syringe. 205 healthy men received one injection with either the pen or a syringe. The results will help…

This study looked at how the diabetes pill Rybelsus® (oral semaglutide) works in real life for adults with type 2 diabetes in Mexico. 187 participants took the medication as prescribed by their doctor and were followed for about 8-10 months. Researchers measured changes in blood …

This study tested whether a once-weekly injection of semaglutide (a diabetes drug) plus a lower dose of insulin works as well as a higher dose of insulin alone for controlling blood sugar. About 568 adults with type 2 diabetes and overweight took part. The goal was to see if addi…

This early-stage study tested a new medicine, NNC0363-1063, in 117 healthy volunteers and people with type 1 diabetes. The goal was to check its safety and how the body processes it. The study had three parts, including single and multiple doses, and a meal test. Results will hel…

This study looked at how well the once-daily pill Rybelsus (oral semaglutide) works in real life for adults with type 2 diabetes in Saudi Arabia. About 194 participants took the medicine as prescribed by their doctor and filled out a questionnaire. The main goal was to see if it …

This study tested a daily 25 mg semaglutide tablet in 307 adults with overweight or obesity to see if it helps with weight loss. Participants took the pill or a placebo for 64 weeks, followed by 7 weeks of follow-up. The main goals were to measure the percentage of weight lost an…

This study tested a new medicine called NNC0519-0130 to help people with excess weight lose weight. About 354 adults who had tried and failed to lose weight before took part. They received 1-2 injections under the skin once a week for up to 42 weeks. The main goal was to see how …

This study tested whether adding a new medicine (NNC0165-1875) to the existing weight-loss drug semaglutide helps people with obesity lose more weight. About 120 adults with a BMI between 30 and 45 took part. Participants received either the new drug plus semaglutide or a placebo…

This study tested a new investigational drug called CagriSema against the approved drug tirzepatide in over 1,000 adults with type 2 diabetes. Participants were randomly assigned to receive weekly injections of either CagriSema or tirzepatide for up to a year and a half. The goal…

This study tested a new medicine called somapacitan, given once a week, against the standard daily growth hormone shot Norditropin in 110 Chinese children with growth hormone deficiency. The goal was to see if the weekly shot works as well as the daily one for helping children gr…

This study tested a daily tablet called semaglutide to help people with overweight or obesity lose weight. About 667 adults took either the real pill or a placebo for 68 weeks, along with diet and exercise advice. The main goal was to see how much weight they lost and if at least…

This study tested a new medicine (NNC0480-0389) combined with semaglutide, an already-approved diabetes drug, in 500 adults with type 2 diabetes. The goal was to see how well different doses lower blood sugar over 34 weeks. Participants gave themselves weekly injections and had r…

This study tested a weekly injection of semaglutide (2.4 mg) to help adults with overweight or obesity lose weight. About 242 participants received either the drug or a placebo for one year. The main goal was to see how much weight they lost and if at least 5% of body weight was …

This study tested several drugs, alone or together, to see if they can reduce liver damage and help people drink less alcohol. About 270 adults with alcohol-related liver disease took part. The goal was to find treatments that improve liver health and reduce harmful drinking.

This study looked at how well three different doses of semaglutide (2 mg, 8 mg, and 16 mg) work in 245 adults with type 2 diabetes and overweight who were already taking metformin. Participants received weekly injections for about 40 weeks. The main goals were to see changes in b…

This study tested a new once-weekly medicine called IcoSema (a mix of two diabetes drugs) against a daily insulin shot in 485 adults with type 2 diabetes whose blood sugar was not well controlled on oral pills. The goal was to see if the weekly shot works as well or better at low…

This study tested a new medicine called CagriSema, a once-weekly injection, in 331 East Asian adults with obesity or overweight. The goal was to see how much weight people lost compared to taking semaglutide alone. The trial lasted about 1.5 years and measured changes in body wei…

This study looked at how well the once-daily pill Rybelsus (oral semaglutide) controls blood sugar in adults with type 2 diabetes. About 194 participants in Sweden took the medicine as prescribed by their doctor and filled out questionnaires during regular visits. The study laste…

This early-stage study tested a new medicine, NNC0519-0130, given as a weekly injection to help people with obesity or type 2 diabetes. 82 participants received either the drug or a placebo to check for side effects and measure changes in body weight and blood sugar. The study is…

This study tested a new medicine (turoctocog alfa pegol) to prevent and treat bleeding in 124 children under 6 with severe haemophilia A who had never received clotting factor before. The goal was to see if the drug is safe and works well. The results help doctors understand how …

This study tested a new long-acting clotting factor drug (NNC-0156-0000-0009) in 25 children with moderate to severe hemophilia B. The goal was to see if the drug is safe and helps prevent or treat bleeding episodes. The children received regular infusions of the drug, and resear…

This study looked at how well the diabetes pill Rybelsus (oral semaglutide) works in real-world settings for adults with type 2 diabetes. Researchers tracked changes in blood sugar levels and body weight over about 8-10 months. Participants took the medication as prescribed by th…

This study looked at how safe and tolerable a weekly injection of semaglutide (a diabetes drug) is for people with type 2 diabetes in Chile. About 104 adults took part, receiving a dose chosen by their doctor for 24 weeks. Researchers tracked side effects and measured changes in …

This study followed 99 adults with type 2 diabetes in Denmark who were already prescribed Rybelsus (oral semaglutide) by their doctor. Researchers tracked changes in blood sugar (HbA1c) and body weight over about 8-10 months. Participants filled out questionnaires during regular …

This study tested a new insulin, icodec, that is injected just once a week, against a standard daily insulin (glargine) in nearly 1,000 adults with type 2 diabetes who had never used insulin before. The goal was to see if the weekly insulin controls blood sugar as well as the dai…

This study looked at the safety and effectiveness of Refixia® in 28 people with Hemophilia B in Japan. Participants received the drug as part of their normal care. Researchers tracked side effects, bleeding episodes, and quality of life. The goal was to confirm the drug works wel…

This study tested a new weekly injection called CagriSema (a mix of two medicines) to help people with overweight or obesity and type 2 diabetes lose weight. About 1,200 adults took part, receiving either CagriSema or a placebo for around 1.5 years. The main goals were to see how…

This study tested a new medicine, NNC0487-0111, in 448 adults with type 2 diabetes. The goal was to see if different doses (given as a weekly injection or daily pill) could safely lower blood sugar and body weight compared to a placebo. The study lasted about 43 weeks and include…

This study tested a high dose (7.2 mg) of semaglutide, a once-weekly injection, in 1407 adults with obesity. Participants received either the high dose, a lower dose, or a placebo, plus lifestyle advice. The main goal was to see how much weight they lost over 72 weeks. Results sh…

This study tested a new medicine called CagriSema (a combination of two drugs) for weight loss in 300 Chinese adults with obesity or overweight. Participants received either CagriSema, a placebo, or semaglutide alone once a week for about a year. The main goal was to see how much…

This study tested a new medicine called Mim8 for people with hemophilia A, a condition where blood does not clot properly. Mim8 is injected under the skin to replace the missing clotting factor and prevent bleeding episodes. The trial included 275 healthy volunteers and people wi…

This study tested a new investigational medicine called CagriSema in 274 adults with type 2 diabetes. Participants took either CagriSema or a placebo once a week, in addition to their usual daily insulin (with or without metformin). The goal was to see if CagriSema could lower bl…

This study tested whether a new combination medicine called CagriSema can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and overweight or obesity. About 626 participants received either CagriSema, one of its two components alone, or a placebo for 35…

This study tested a new medicine called Mim8 in 281 adults and teens with hemophilia A, including those whose bodies have developed inhibitors that block standard treatment. Mim8 is given as a weekly or monthly injection under the skin to help prevent bleeding episodes by replaci…

This study tested a new drug called NNC0487-0111, given as a shot under the skin, to see if it is safe and how it works in people who are overweight or obese. The trial involved 125 adults aged 18-55 with a BMI between 27 and 40. The main goal was to check for side effects and me…

This study tested a new weekly injection called CagriSema, which combines two medicines (semaglutide and cagrilintide), in over 2,700 adults with type 2 diabetes. The goal was to see if CagriSema lowers blood sugar and body weight better than either medicine alone or a placebo. P…

This study tested a new once-weekly medicine called IcoSema (a mix of insulin and another drug) against daily insulin in 679 adults with type 2 diabetes whose blood sugar was not well controlled. Participants received either IcoSema weekly or daily insulin plus mealtime insulin f…

This study looked at whether using a smartphone app called 'Dose Check' together with the insulin Tresiba helps people with type 2 diabetes control their blood sugar. About 179 adults in Saudi Arabia took part for 6-7 months. The app helped them figure out the correct insulin dos…

This study tested a weekly injection of semaglutide (a weight-loss medicine) in 201 teenagers aged 12 to 17 with overweight or obesity. Over 15 months, participants received either the drug or a placebo, plus lifestyle advice. The main goal was to see how much their body mass ind…

This study tested whether a new way of making semaglutide works as well as the current version for controlling blood sugar. About 388 adults with type 2 diabetes received weekly injections for 28 weeks. The main goal was to see if the new version lowers blood sugar (HbA1c) just a…

This study tested a medicine called turoctocog alfa pegol (N8-GP) in 36 Chinese men with severe hemophilia A. The drug helps blood clot and was given as a shot into a vein to both treat and prevent bleeding episodes. Over about 7-8 months, researchers measured how many bleeds occ…

This study tested how easy and convenient the DuraTouch® device is for people with type 1 or type 2 diabetes. 128 participants used the device for about 12 weeks and rated their satisfaction. The goal was to see if the device is simple to prepare and inject, and if users feel con…

This study compared a new medicine called dasiglucagon to the standard glucagon shot for treating severe low blood sugar in 38 Asian adults and Japanese teens with type 1 diabetes. Both medicines are designed to quickly raise blood sugar during emergencies. The goal was to see if…

This study tested a weekly medicine called semaglutide in 617 people with obesity-related heart failure and type 2 diabetes. The goal was to see if it improves heart failure symptoms and helps with weight loss. Participants received either the medicine or a placebo for about a ye…

This study tested whether semaglutide, a diabetes medicine, can improve walking ability in people with type 2 diabetes and peripheral arterial disease (PAD), which causes leg pain when walking. About 792 adults received either semaglutide or a placebo injection once a week for ab…

This study tested whether a combination of two medicines, cagrilintide and semaglutide (called CagriSema), can reduce how much people eat and their appetite. 62 adults with overweight or obesity were randomly assigned to receive either CagriSema or a placebo for about 32 weeks. T…

This study tested a weekly injection of semaglutide in 529 adults with obesity and a type of heart failure where the heart pumps normally but doesn't fill properly. The goal was to see if the drug improves heart failure symptoms, daily function, and body weight compared to a plac…

This early-stage study tested a new medicine called NNC0487-0111 in 36 Chinese adults who were overweight or obese. The main goal was to check if the drug is safe and how the body processes it. Participants received either the medicine or a placebo, and the study lasted up to 53 …

This early-stage study tested a single injection of a new medicine called NNC0662-0419 in 100 adults who are overweight or obese. Researchers measured how much of the drug stayed in the blood and checked for side effects. The study included Japanese, Chinese, and non-Asian partic…

This study looked at how different amounts of water and delays before breakfast affect levels of a new semaglutide tablet in the blood. 121 healthy men took the tablet daily for 10 days, with varying water volumes (50 or 120 mL) and meal delays (30, 60, or 120 minutes). The goal …

This study tested whether a new medicine called etavopivat changes how the body processes five common drugs: digoxin, pitavastatin, metformin, midazolam, and rosuvastatin. Thirty-seven healthy adults took etavopivat daily for 10 days along with single doses of each common drug. T…

This study looks at how the body handles a single dose of the experimental drug etavopivat in people with mild, moderate, or severe liver problems compared to those with healthy livers. 48 adults took one pill by mouth and were monitored for about a week. The goal is to understan…

This study tested four different tablet versions of the medicine semaglutide in 90 healthy men. The goal was to see how each tablet is absorbed into the body, not to treat any disease. Participants were randomly assigned to a tablet version and followed for about 28 weeks.

This study looked at two weight-loss medicines, cagrilintide and semaglutide, given to 40 adults with overweight or obesity. For 14 weeks, everyone got two separate shots. Then, for 8 weeks, some got a single combined shot while others kept getting two shots. The goal was to see …

This completed Phase 1 study tested two different forms of the experimental drug NNC0519-0130 in 46 adults with overweight or obesity. The main goal was to measure how much of each version gets into the blood, not to treat or cure obesity. Participants received both formulations …

This study tested the safety of a new medicine, Inno8, in 95 healthy men aged 18-45. Participants received either Inno8 or a placebo by injection or as tablets. The goal was to check for side effects and how the drug moves through the body, which will help plan future studies in …

This study follows people who took part in the SELECT obesity trial to see how their health changes over the next 10 years. No new medicine is given; participants simply fill out a health questionnaire every 6 months. The goal is to learn about long-term effects on weight, heart …

This study looked at how common heart disease is in people with obesity in Saudi Arabia. About 1,061 adults with obesity answered questions about their health and lifestyle during a routine doctor visit. The goal was to collect information, not to test a treatment. Participants h…

This study tested a single dose of a new medicine called NNC0519-0130 in 36 adults with type 2 diabetes and varying levels of kidney function. Researchers measured how much of the drug stayed in the blood to see if kidney problems change how the body handles it. The goal is to he…

This study surveyed 1,500 cardiologists and nephrologists in China to understand their awareness and perceptions of systemic inflammation in patients with both atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). The goal was to see how doctors identif…

This study looked at how a combination of two medicines, cagrilintide and semaglutide (called CagriSema), affects appetite and brain activity in 164 adults with overweight or obesity. Participants received either CagriSema, a dummy medicine, or no medicine, and researchers measur…

This study looked at medical records of over 1,300 adults with obesity in the Gulf region to find out how often they have related health problems like diabetes, high blood pressure, and fatty liver disease. It also measured the healthcare costs linked to these conditions. The goa…

This study looked at whether a new medicine called NNC0519-0130 changes how the body processes a common birth control pill and how fast the stomach empties. It involved 47 healthy postmenopausal women who took the study drug, birth control pills, and paracetamol over about 35 wee…

This study tested a single dose of the experimental drug monlunabant in 73 healthy men of normal weight, half Japanese and half Caucasian. The main goal was to check safety and how the drug moves through the body, not to treat obesity. Participants received either the drug, a pla…

This study looked at how a new medicine called etavopivat affects the heart's electrical activity. It involved 33 healthy adults aged 18 to 55. Participants received different doses of the medicine, a placebo, or an approved heart drug to compare effects. The goal was to ensure t…

This study tested a new long-acting insulin called insulin icodec in 18 children and teens (ages 10 to under 18) with type 2 diabetes. Participants received a single injection, and researchers measured how the drug moves through the body over about 8 weeks. The goal was to gather…

This early-stage study tested a new medicine called NNC0581-0001 in 48 adults to see if it is safe and how the body handles it. Some participants were healthy, and others had fatty liver (hepatic steatosis). Each person received either the drug or a placebo as a single injection …

This early-stage study tested a new experimental drug, NNC0113-6856, in 70 healthy men to see if it is safe and how it moves through the body. Participants received either a single oral dose or an injection into a vein. The goal was to gather initial safety data and measure drug …